Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dose-escalation study of KER-050 for anemia in lower-risk myelodysplastic syndromes
MOH_2021-06-14_009950Phase 2Active, not recruiting
- Sponsor
- Keros Therapeutics
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of elritercept in myelodysplastic syndrome (MDS) (2 arms), sponsored by Keros Therapeutics. Primary endpoints: Safety and tolerability in Part 1 and Safety and tolerability in Part 2. Started May 2021; status: active, not recruiting.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2021-06-14_009950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-14_009950.